Leek J, Lench N, Maraj B, Bailey A, Carr I M, Andersen S, Cross J, Whelan P, MacLennan K A, Meredith D M
Molecular Medicine Unit, University of Leeds, UK.
Br J Cancer. 1995 Sep;72(3):583-8. doi: 10.1038/bjc.1995.377.
Prostate-specific membrane antigen (PSM) is a glycoprotein recognised by the prostate-specific monoclonal antibody 7E11-C5, which was raised against the human prostatic carcinoma cell line LNCaP. A cDNA clone for PSM has been described. PSM is of clinical importance for a number of reasons. Radiolabelled antibody is being evaluated both as an imaging agent and as an immunotherapeutic in prostate cancer. Use of the PSM promoter has been advocated for gene therapy applications to drive prostate-specific gene expression. Although PSM is expressed in normal prostate as well as in primary and secondary prostatic carcinoma, different splice variants in malignant tissue afford the prospect of developing reverse transcription-polymerase chain reaction (RT-PCR)-based diagnostic screens for the presence of prostatic carcinoma cells in the circulation. We have undertaken characterisation of the gene for PSM in view of the protein's interesting characteristics. Unexpectedly, we have found that there are other sequences apparently related to PSM in the human genome and that PSM genomic clones map to two separate and distinct loci on human chromosome 11. Investigation of the function of putative PSM-related genes will be necessary to enable us to define fully the role of PSM itself in the development of prostatic carcinoma and in the clinical management of this malignancy.
前列腺特异性膜抗原(PSM)是一种糖蛋白,可被前列腺特异性单克隆抗体7E11-C5识别,该抗体是针对人前列腺癌细胞系LNCaP产生的。已描述了PSM的cDNA克隆。PSM具有临床重要性,原因如下。放射性标记抗体正在作为前列腺癌的成像剂和免疫治疗剂进行评估。有人主张将PSM启动子用于基因治疗应用,以驱动前列腺特异性基因表达。虽然PSM在正常前列腺以及原发性和继发性前列腺癌中均有表达,但恶性组织中的不同剪接变体为开发基于逆转录-聚合酶链反应(RT-PCR)的诊断筛查方法以检测循环中前列腺癌细胞的存在提供了前景。鉴于该蛋白的有趣特性,我们对PSM基因进行了表征。出乎意料的是,我们发现人类基因组中还有其他与PSM明显相关的序列,并且PSM基因组克隆定位于人类11号染色体上两个独立且不同的位点。为了使我们能够全面定义PSM本身在前列腺癌发生发展以及该恶性肿瘤临床管理中的作用,有必要对假定的PSM相关基因的功能进行研究。